Compare Amphastar Pharmaceuticals Inc (AMPH) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Schwab US Large Cap Growth ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.38 (market cap $826.08M), while Schwab US Large Cap Growth ETF trades at $34.59. The key difference: Schwab US Large Cap Growth ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | SCHG | |
|---|---|---|
Market Cap | $826.08M | — |
Sector | Health | Sector/Thematic |
52-Week High | $30.81 | $35.30 |
52-Week Low | $16.87 | $28.10 |
Enterprise Value | $1.22B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
SCHG trades at $34.65 with a 0.32% daily gain, showing bullish technical momentum with strong moving average support. The ETF's concentrated exposure to AI-driven tech leaders like Nvidia, Apple, and Microsoft positions it for growth amid projected multi-trillion dollar AI infrastructure spending. Recent institutional buying and positive analyst coverage highlight confidence in its large-cap growth strategy despite elevated valuations around 32x P/E.
The outlook remains positive given SCHG's strategic positioning in AI growth themes, though concentration risk in top holdings and sensitivity to interest rate changes present challenges. Current technical strength suggests near-term upside potential to resistance at $35, while long-term performance depends on sustained tech sector leadership and AI adoption trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
